MS Briefs

Exposure to passive smoking during adolescence tied to MS risk


 

Key clinical point : Exposure to passive smoking during adolescence is a strong risk factor for developing multiple sclerosis (MS) in later life.

Major finding : Among never smokers, female patients with MS more often than healthy control participants reported exposure to passive smoking between the age of 10 and 19 years (women: odds ratio [OR], 1.432; P = .037 and men: OR, 1.232; P = .390). Among active smokers aged 19 years or older, male MS patients more often than male control participants reported with passive smoking (men: OR, 1.593; P = .022 and women: OR, 1.102; P = .440).

Study details : The data come from a case-control study of 919 MS cases and 3,419 controls (never active smokers: 342/822 cases/controls; active smokers aged 19 years or older: 577/2,597 cases/controls).

Disclosures: This study was supported by grants from the Danish Multiple Sclerosis Society, the Danish Council for Strategic Research, Novartis, Biogen (Denmark), the Sofus Carl Emil Friis og Hustru Olga Doris Friis foundation, the Foundation for Research in Neurology, and the Director Einar Jonasson (Johnsen) and Wife foundation. Some of the authors reported receiving research support from various pharmaceutical companies.

Citation: Oturai DB et al. Mult Scler. 2020 Mar 23. doi: 10.1177/1352458520912500.

Recommended Reading

Does diet quality influence late-onset MS risk?
ICYMI Multiple Sclerosis
N-acetyl cysteine may positively affect cerebral glucose metabolism in MS
ICYMI Multiple Sclerosis
FDA approves ozanimod for relapsing and secondary progressive forms of MS
ICYMI Multiple Sclerosis
MS: Trends in the use of disease-modifying agents
ICYMI Multiple Sclerosis
Cancer risks with biological therapies for MS
ICYMI Multiple Sclerosis
High serum homocysteine levels in patients with MS
ICYMI Multiple Sclerosis
MS in pregnancy: Maintenance of natalizumab during the first trimester is beneficial
ICYMI Multiple Sclerosis
Serum vitamin D inversely associated with clinical and disease activity in MS
ICYMI Multiple Sclerosis
Fingolimod vs. natalizumab as second-line therapy for RRMS
ICYMI Multiple Sclerosis
Physical exercise reduces fatigue in patients with MS
ICYMI Multiple Sclerosis